GlassScriptPhysician profile
Glen J Kesler
NPI 1427075423
$982.86
in general payments reported to CMS, 2019-2025
26 companies · $84.11 in 2025
The $84.11 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.80 · 2021: $293 · 2022: $209 · 2023: $249 · 2024: $49.95 · 2025: $84.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $159.14 | 2021-2023 | |
| Novo Nordisk INC | $156.40 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $122.26 | 2023 | Breztri |
| Janssen Pharmaceuticals, INC | $60.70 | 2019-2022 | |
| Abbvie INC. | $57.23 | 2022-2025 | |
| Csl Behring | $42.81 | 2021 | |
| Exact Sciences Corporation | $41.93 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $34.47 | 2022 | |
| Glaxosmithkline, LLC. | $31.99 | 2022-2023 | Arexvy, Shingrix |
| Abbott Laboratories | $24.84 | 2023 | Freestyle Libre |
| Hikma Pharmaceuticals USA | $23.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.80 | 2024 | Xifaxan |
| Siemens Medical Solutions USA, INC. | $19.63 | 2022 | |
| Dexcom, INC. | $18.46 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.33 | 2022 | |
| Bausch Health US, LLC | $15.93 | 2022 | |
| Lilly USA, LLC | $15.46 | 2022 | |
| Merck Sharp & Dohme LLC | $14.76 | 2019 | |
| Antares Pharma, INC. | $14.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.88 | 2023 | Nuzyra |
| Astellas Pharma US INC | $13.87 | 2023 | Veozah |
| Inspire Medical Systems, INC. | $13.20 | 2024 | Inspire |
| Arbor Pharmaceuticals, INC. | $12.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $7.31 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Kesler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.